FTH
Faeth Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.44
+3.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (4.9M) | — | — | — | — |
| Cost of Revenue | 128.1M | — | 551.0K | 571.0K | 1.8M |
| Gross Profit | (133.0M) | — | (551.0K) | (571.0K) | (1.8M) |
| Operating Expenses | |||||
| R&D Expense | 31.8M | 11.0M | 18.6M | 18.3M | 29.6M |
| SG&A Expense | 34.0M | 11.3M | 12.5M | 18.8M | 17.7M |
| General & Admin Expense | 34.0M | 11.3M | — | 18.7M | — |
| Selling & Marketing Expense | — | — | — | 100.0K | — |
| Other Expenses | — | — | — | (571.0K) | — |
| Total Operating Expenses | 65.9M | 22.3M | 31.1M | 36.5M | 47.3M |
| Cost and Expenses | 194.0M | 22.3M | 31.7M | 37.1M | 49.1M |
| Operating Income (EBIT) | (198.8M) | (22.3M) | (31.7M) | (37.1M) | (49.1M) |
| Non-Operating | |||||
| Interest Income | 3.2M | 1.2M | 2.5M | 3.6M | 1.8M |
| Interest Expense | 9.0K | 32.0K | 90.0K | 144.0K | 219.0K |
| Net Interest Income | 3.2M | 1.2M | 2.5M | 3.5M | 1.6M |
| Other Non-Op Income/Expense | 3.3M | 1.2M | 1.5M | 3.0M | 532.0K |
| Non-Operating Income (excl Interest) | (3.3M) | (1.2M) | (1.6M) | (100.0K) | (751.0K) |
| EBT (Pre-Tax Income) | (195.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (195.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Earnings from Cont. Ops | (195.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (195.5M) | (21.1M) | (30.2M) | (34.1M) | (48.6M) |
| Per Share | |||||
| Basic EPS | ($141.65) | ($16.72) | ($24.01) | ($24.40) | ($31.65) |
| Diluted EPS | ($141.65) | ($16.72) | ($24.01) | ($24.40) | ($31.65) |
| Revenue Per Share | ($0.86) | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.6M | 1.3M | 1.3M | 1.4M | 1.5M |
| Diluted Shares Outstanding | 5.6M | 1.3M | 1.3M | 1.4M | 1.5M |
| Profitability Metrics | |||||
| EBITDA | (195.4M) | (20.9M) | (28.7M) | (35.6M) | (47.0M) |
| D&A | 122.0K | 139.0K | 1.3M | 1.4M | 1.3M |
| EBIT | (195.5M) | (21.1M) | (30.1M) | (37.0M) | (48.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026